Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 43.2063
- Book/Share 64.2129
- PB 7.1149
- Debt/Equity 0.1
- CurrentRatio 2.6456
- ROIC -0.128
- MktCap 117322845390.0
- FreeCF/Share -4.8968
- PFCF -93.2614
- PE -118.6873
- Debt/Assets 0.0721
- DivYield 0
- ROE -0.0625
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VRTX | Wolfe Research | Outperform | Peer Perform | -- | -- | May 7, 2025 |
| Downgrade | VRTX | Leerink Partners | Outperform | Market Perform | -- | $503 | May 6, 2025 |
| Resumed | VRTX | Cantor Fitzgerald | -- | Overweight | -- | $535 | April 22, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | $408 | $424 | Feb. 12, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | -- | -- | Feb. 11, 2025 |
| Downgrade | VRTX | Wells Fargo | Overweight | Equal Weight | -- | $460 | Jan. 30, 2025 |
| Reiterated | VRTX | H.C. Wainwright | -- | Buy | $600 | $535 | Dec. 20, 2024 |
| Downgrade | VRTX | Oppenheimer | Outperform | Perform | -- | -- | Dec. 19, 2024 |
| Upgrade | VRTX | Jefferies | Hold | Buy | $500 | $550 | Dec. 9, 2024 |
| Initiation | VRTX | Scotiabank | -- | Sector Perform | -- | -- | Oct. 16, 2024 |
News
Why Vertex Pharmaceuticals Stock Is Sinking Today
Published: May 06, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Vertex Pharmaceuticals (VRTX -11.69%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday.
Read More
Rising Costs Weigh on Vertex Q1 Earnings
Published: May 06, 2025 by: The Motley Fool
Sentiment: Neutral
Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report.
Read More
Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward.
Read More
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Published: April 30, 2025 by: CNBC Television
Sentiment: Neutral
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!
Read More
What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Getting dizzy from the stock market's gyrations? Join the club.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Read More
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right
Published: April 22, 2025 by: The Motley Fool
Sentiment: Negative
President Trump isn't a fan of Fed Chairman Jerome Powell, despite nominating Powell to replace Janet Yellen in 2017. Trump recently called Powell a "major loser" on a social media post and demanded that he lower interest rates immediately.
Read More
Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike
Published: April 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch in this volatile markets.
Read More
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Read More
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.
Published: April 04, 2025 by: The Motley Fool
Sentiment: Neutral
Which group of individuals is in the best position to spot early warning signs of economic trouble? There's a good case to be made for corporate chief financial officers (CFOs).
Read More
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.
Read More
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Published: March 24, 2025 by: CNBC Television
Sentiment: Positive
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
Read More
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.
Read More
Final Trades: Netflix, Meta, Vertex, Interactive Brokers and the COWZ
Published: March 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink's Global Healthcare Conference 2025 March 10, 2025 10:00 AM ET Company Participants Charlie Wagner - CFO and COO David Altshuler - Chief Scientific Officer Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger Great. Well thanks very much, everyone, for joining us for our next session with Vertex.
Read More
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company's 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Published: February 21, 2025 by: The Motley Fool
Sentiment: Positive
Looking for a good area in which to invest? Consider the healthcare sector.
Read More
GILD or VRTX: Which Is the Better Value Stock Right Now?
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
3 Stocks That Could Trounce the Market in 2025
Published: February 17, 2025 by: The Motley Fool
Sentiment: Positive
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Read More
The Ultimate Healthcare Stock to Buy With $500 Right Now
Published: February 14, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Reshma Kewalramani FASN,
- Employees 6100